An Integrative Computational Approach Based on Expression Similarity Signatures to Identify Protein-Protein Interaction Networks in Female-Specific Cancers.
TCGA
bioinformatics
breast cancer
endometrial cancer
molecular signatures
ovarian cancer
principal component analysis - PCA
signaling pathway
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
09
2020
accepted:
28
10
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
12
1
2021
Statut:
epublish
Résumé
Breast, ovarian, and endometrial cancers have a major impact on mortality in women. These tumors share hormone-dependent mechanisms involved in female-specific cancers which support tumor growth in a different manner. Integrated computational approaches may allow us to better detect genomic similarities between these different female-specific cancers, helping us to deliver more sophisticated diagnosis and precise treatments. Recently, several initiatives of The Cancer Genome Atlas (TCGA) have encouraged integrated analyses of multiple cancers rather than individual tumors. These studies revealed common genetic alterations (driver genes) even in clinically distinct entities such as breast, ovarian, and endometrial cancers. In this study, we aimed to identify expression similarity signatures by extracting common genes among TCGA breast (BRCA), ovarian (OV), and uterine corpus endometrial carcinoma (UCEC) cohorts and infer co-regulatory protein-protein interaction networks that might have a relationship with the estrogen signaling pathway. Thus, we carried out an unsupervised principal component analysis (PCA)-based computational approach, using RNA sequencing data of 2,015 female cancer and 148 normal samples, in order to simultaneously capture the data heterogeneity of intertumors. Firstly, we identified tumor-associated genes from gene expression profiles. Secondly, we investigated the signaling pathways and co-regulatory protein-protein interaction networks underlying these three cancers by leveraging the Ingenuity Pathway Analysis software. In detail, we discovered 1,643 expression similarity signatures (638 downregulated and 1,005 upregulated genes, with respect to normal phenotype), denoted as tumor-associated genes. Through functional genomic analyses, we assessed that these genes were involved in the regulation of cell-cycle-dependent mechanisms, including metaphase kinetochore formation and estrogen-dependent S-phase entry. Furthermore, we generated putative co-regulatory protein-protein interaction networks, based on upstream regulators such as the ERBB2/HER2 gene. Moreover, we provided an
Identifiants
pubmed: 33424936
doi: 10.3389/fgene.2020.612521
pmc: PMC7793872
doi:
Types de publication
Journal Article
Langues
eng
Pagination
612521Informations de copyright
Copyright © 2020 Pane, Affinito, Zanfardino, Castaldo, Incoronato, Salvatore and Franzese.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
PeerJ. 2020 Jan 9;8:e8347
pubmed: 31942259
Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):E283-90
pubmed: 24371309
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
Am J Cancer Res. 2015 Sep 15;5(10):2929-43
pubmed: 26693050
Physiol Rev. 2017 Jul 1;97(3):1045-1087
pubmed: 28539435
BMC Cancer. 2015 Jul 14;15:516
pubmed: 26169172
Int J Gynecol Pathol. 2017 Jul;36(4):356-363
pubmed: 28221216
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Cell. 2015 Oct 8;163(2):506-19
pubmed: 26451490
Int J Mol Sci. 2017 Apr 12;18(4):
pubmed: 28417933
Int J Mol Sci. 2020 Sep 12;21(18):
pubmed: 32932728
Oncogene. 2003 Apr 17;22(15):2361-73
pubmed: 12700671
Brief Bioinform. 2019 May 21;20(3):806-824
pubmed: 29186305
Lancet. 2017 Feb 25;389(10071):847-860
pubmed: 27814965
Curr Opin Cell Biol. 2018 Oct;54:1-8
pubmed: 29477121
BMC Genomics. 2015;16 Suppl 5:S2
pubmed: 26040466
PLoS One. 2018 Jan 30;13(1):e0191972
pubmed: 29381731
Exp Hematol Oncol. 2018 Sep 19;7:24
pubmed: 30250760
Endocr Relat Cancer. 2019 Feb 1;26(4):451-462
pubmed: 30753136
CA Cancer J Clin. 2019 Nov;69(6):438-451
pubmed: 31577379
J Mol Endocrinol. 2016 Feb;56(2):R55-71
pubmed: 26826253
Biomed Res Int. 2013;2013:510905
pubmed: 24222909
PeerJ. 2019 Jun 6;7:e6872
pubmed: 31205821
Genomics. 2008 Dec;92(6):400-3
pubmed: 18565726
Cold Spring Harb Perspect Biol. 2016 Aug 01;8(8):
pubmed: 26988969
Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4834-9
pubmed: 19261849
BMC Syst Biol. 2018 Apr 11;12(Suppl 1):8
pubmed: 29671401
Cancer Treat Rev. 2014 Jul;40(6):770-80
pubmed: 24656976
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Contemp Oncol (Pozn). 2015;19(1A):A68-77
pubmed: 25691825
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Cancer Cell. 2018 Apr 9;33(4):690-705.e9
pubmed: 29622464
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
J Transl Med. 2019 Oct 7;17(1):337
pubmed: 31590671
Cell Mol Life Sci. 2013 Feb;70(4):559-79
pubmed: 22752158
Nat Rev Cancer. 2019 Jun;19(6):326-338
pubmed: 31053804
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
Curr Opin Obstet Gynecol. 2020 Feb;32(1):57-64
pubmed: 31833974
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
pubmed: 18698038